Looks like Part D won’t kill off patient assistance programs after all
Pharmaceutical companies have extensive, if sometimes not fully understood, patient assistance programs that provide low-income/uninsured patients with access to drugs. With the advent of Medicare’s Part D prescription drug program it looked like those programs were going to fall by the wayside, at least for senior citizens.
But politicians have picked up on the issue and in recent days GlaxoSmithKline, AstraZeneca and Lilly have announced changes to their policies to allow low-income Part D recipients to qualify.
See PharmaLive for more.May 12, 2006